insights_auto
Zašto je ANW pao 33,90%?
Istražite detaljnijechevron_right
ANW:FRA
Immuron Ltd
0,020 €
arrow_downward
−33,90%(−0,010) 1D
13. lis, 22:00:00 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za ANW...
Otvori
0,02 €
Najviša
0,02 €
Najniža
0,02 €
Trž. kap.
12,88 mil.
Prosj. kol.
627,00
Količina
0,00
52-tjed. najviša
0,04 €
52-tjed. najniža
0,01 €
Broj djelatnika
8
Otvori
0,02 €
Najviša
0,02 €
Najniža
0,02 €
Trž. kap.
12,88 mil.
Prosj. kol.
627,00
Količina
0,00
52-tjed. najviša
0,04 €
52-tjed. najniža
0,01 €
Broj djelatnika
8
Vijesti
Iz web-izvora i od partnera za vijesti
Stock Titan
·
prije 19 sati
A travel-diarrhea pill showed 50% less severe diarrhea, but missed its main trial goals
TipRanks
·
prije 1 dan
Immuron advances Travelan after Phase 2 data published in Nature journal
Profil
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Immuron Ltd – informacije
Glavni izvršni direktor-
Zaposlenici8
Osnovano1994
SjedišteBlackburn North, Victoria, Australija
Sektor-
Web-lokacijaimmuron.com.au